Accelerate Diagnostics announces sizeable release of new data at ECCMID 2018
Four integrated symposium sessions, 11 poster presentations, and case studies will cover the clinical value of integrating diagnostic stewardship into current sepsis protocols given the rising rates of antibiotic resistance
TUCSON, Ariz., April 21, 2018 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. today announced the sizeable release of new data presented by the company, its customers, and clinical experts during the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2018, located in IFEMA – Feria de Madrid, Madrid, Spain, April 21 – 24th.
The symposium presentations on Monday, April 23, 9 – 11 a.m., in Hall L,
will focus on best practices in the management of hospitalized patients with bacteremia using integrating diagnostics, sepsis protocols and antimicrobial stewardship. All presentations will be followed by Q & A sessions.
The first presentation, held 9:05 – 9:25 a.m., “Challenges of Antibiotic Stewardship in the Critically Ill,” will be presented by Professor Jan De Waele of Ghent University, Ghent, Belgium.
The second presentation, held 9:45 – 9:55 a.m., “Individualized Antibiotic Therapy in Critical Care Presented,” will be presented by Professor Fabio Taccone, ULB of Hôpital Erasme, Brussels, Belgium.
The third presentation, held from 9:55 – 10:20 a.m., “Case Studies in Bacteremia, Sepsis and Septic Shock,” will be presented by Dr. Claire Thomas of Hampshire Hospitals NHS Foundation Trust, Basingstoke, United Kingdom.
The fourth presentation, held from 10:20 to 10:30 a.m., “Critical Need to Develop Susceptibility Testing Capacity in Clinical Laboratories” will be presented by Dr. Romney Humphries of Accelerate Diagnostics, Tucson, USA.
Learn more or register to attend these events at: http://eccmid-congress.org
11 poster presentations featuring performance of the Accelerate Pheno™ system will be presented throughout the conference:
E0126 — Diagnostic accuracy of Accelerate Pheno™ system on antimicrobial susceptibility testing in comparison to broth microdilution method.
Presented by: Tianyan Song; Tor Monsen
O0276 — MDR – XDR – PDR Gram-negatives Association between identification and antibiotics susceptibility testing with Accelerate Pheno™ system and the antimicrobial management of patients with severe sepsis from the Hospital Universitario de La Princesa.
Presented by: Nelly Daniela Zurita Cruz; Laura Llorca; Sara Gómez de Frutos; Tamara Soler Maniega; María Carmen De las Cuevas; Laura Cardeñoso.
April 21, 4:54 p.m – 4:59 p.m., E-poster Arena 3
O0403 — Novel experience in diagnosing bloodstream infection pathogens.
Performance of the Accelerate Pheno™ system with five new antimicrobials for Enterobacteriaceae tested directly from positive blood cultures.
Presented by: Dulini Gamage; Niels Oppermann; Andrew Ghusson; Aaron Sikorski, Jesse Posey; Lindsey O’Heron; Justin Towne. April 22, 12:18 – 12:28 p.m., Hall H
O0749 — Rapid antimicrobial susceptibility testing – state of the art.
Assessing the clinical impact of rapid pathogen identification (ID) and antimicrobial susceptibility testing (AST) provided by the Accelerate Pheno™ system at Hampshire Hospitals NHS Foundation Trust (HHFT).
Presented by: Stephen Peter Kidd; Stephen Poole; Nathan Moore; Christina Petridou, Kordo Saeed; Claire Thomas; Nick Cortes; Nicki Hutchinson.
April 23, 12:00 – 12:05 p.m., E-poster Arena 2
P1788 — Rapid antimicrobial susceptibility testing – what can we expect?
Comparative evaluation of Accelerate Pheno™ system and Vitek® 2 systems for rapid antibiotic susceptibility testing of pathogens in positive blood cultures.
Presented by: Giulia De Angelis; Teresa Spanu; Tiziana D’Inzeo; Giulia Menchinelli; Patrizia Posteraro; Gabriella Parisi; Maurizio Sanguinett; Brunella Posteraro. ECCMID Poster Hall
P1791 — Rapid antimicrobial susceptibility testing comparison of the Accelerate Pheno™ system test results from Gram-negative bacilli (GNB) parallel-seeded to FA-plus blood culture bottles (BCB) incubated in bioMerieux BacT/Alert-3D and VirtuO systems.
Presented by: Barbara M. Willey; Anthony Oppedisano; Ebuka Osuji; Yaroslav Sokolskyy; Mustafa Al-Ani; Herman Ng; Aimee Paterson; Pauline Lo; Tony Mazzulli; Susan Poutanen. ECCMID Poster Hall
P1796 — Rapid antimicrobial susceptibility testing
Accelerating time-to-pathogen-adapted antibiotic treatment through subculture-independent phenotypic AST in patients suffering from sepsis.
Presented by: Matthias Karrasch; Marco Bender; Jennifer Geraci; Jürgen Rödel; Frank Martin Brunkhorst; Bettina Löffler. ECCMID Poster Hall
P1937 — Rapid antimicrobial susceptibility testing
Comparison of the Accelerate Pheno™ system with the conventional methods for the identification and antimicrobial susceptibility testing of positive blood cultures.
Presented by: Mirko Buttrini; Adriana Calderaro; Monica Martinelli; Silvia Covan; Sara Montecchini; Alberto Ruggeri; Maria Cristina Arcangeletti; Flora De Conto; Carlo Chezzi. ECCMID Poster Hall
P1944 — Diagnostic approaches in bacterial bloodstream infection
Evaluation of the Accelerate Pheno™ system for the diagnosis of bloodstream infections (BSIs) in bacterial bloodstream infection.
Presented by: Giuseppe Giuliani; Marina Re; Luisa Re; Cristina Rescaldani; Lora Manolia; Roberto Ottaviano. ECCMID Poster Hall
P1949 — Diagnostic approaches in bacterial bloodstream infection.
Evaluation of Accelerate Pheno™ system, a rapid identification and antibiotic susceptibility testing (AST) system, in the Hospital Universatario de la Princesa.
Presented by: Nelly Daniela Zurita Cruz; Laura Llorca; Sara Gómez de Frutos; Belén Fernández-Caso; Tamara Soler Maniega; María Carmen De las Cuevas; Laura Cardeñoso. ECCMID Poster Hall
P1951 — Diagnostic approaches in bacterial bloodstream infection
Accelerate Pheno™ system test: the experience of the microbiology and virology laboratory – San Camillo Hospital – Rome.
Presented by: Paola Maria Placanica; Gabriella Parisi; Bruno Mariani; Rosa Maria Oliverio; Mariarosa Gaudio; Daniela Orazi. ECCMID Poster Hall
About the Congress
Recognized as the largest European congress covering its fields, ECCMID is the 28th European Congress of Clinical Microbiology and Infectious Diseases, organized on April 21 and lasting till 24 April 2018 in Madrid, Spain. The congress, hosted by the European Society for Clinical Microbiology and Infectious Diseases (ESCMID), is expected to attract more than 12,000 clinical investigators, scientists and medical professionals related to the fields of microbiology and infectious diseases. The congress focuses on sharing and delivering educational sessions on recent advancements in research and clinical experience in the field of infectious diseases, infection control and clinical microbiology.
For more information visit www.eccmid.org or search #ECCMID2018.
About Accelerate Diagnostics, Inc.
Accelerate Diagnostics, Inc. (Nasdaq:AXDX), is an in vitro diagnostics company dedicated to providing solutions for the global challenge of antibiotic resistance and healthcare-associated infections. The company recently obtained FDA marketing authorization for antimicrobial susceptibility testing direct from positive blood culture samples using its Accelerate PhenoTM system and Accelerate PhenoTestTM BC kit. The system and kit leverage proprietary molecular identification methods and morphokinetic cellular analysis (MCA) to provide minimum inhibitory concentrations for a range of applicable antibiotics. The fully-automated system is designed to eliminate the lengthy culture and sample preparation steps required prior to antimicrobial susceptibility testing. Recent studies suggest the solution offers results 1-2 days faster than conventional methods, enabling clinicians to optimize antibiotic selection, dosage, and infusion strategy specific to the individual patient and their infection.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
Media Contact: Andrew Chasteen, Accelerate Diagnostics, email@example.com, +1 520 404-0809